FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989184576> ?p ?o ?g. }

• W2989184576 endingPage "233.e1" @default.
• W2989184576 startingPage "226" @default.
• W2989184576 abstract "•There is no medical treatment that benefits HFpEF outcomes. •Global longitudinal strain impairment with heart failure occurs in HFpEF model rats. •ACE-I is beneficial after longitudinal strain but before circumferential strain impairment. •Myocardial strain could be the marker for point of no return for HFpEF treatment. Background There are currently no therapies that can improve prognosis in cases of heart failure (HF) with preserved ejection fraction (EF). We hypothesized that there is a point of no return after which no response to treatment is noted and that for the prevention of hypertensive HF this point may be determined by left ventricle (LV) strain, in the prevention of hypertensive HF. Here an angiotensin-converting enzyme inhibitor (ACE-I) was initiated based on myocardial strain imaging and its effects were determined in an animal model. Methods Thirty-two male Dahl salt-sensitive rats, age 6 weeks, were divided into six experimental groups and compared with low-salt (n = 8) and high-salt control groups (n = 8). In the early treatment group, ACE-I was administered from the age of 6 weeks (n = 4); in the longitudinal strain (LS) group, at 10-12 weeks when LS impairment was >–21% (n = 4); in the circumferential strain (CS) group, at 16-18 weeks when CS impairment was >–18% (n = 4); and in the EF group, at 20 weeks when EF was <55% (n = 4). Subsequently, all rats were sacrificed at 23 weeks age, the LV and lung weight were measured, and pathologic analyses were performed. Results At 23 weeks of age, the lung and LV weights increased in the high-salt control, EF, and CS groups, whereas the lung and LV weights in the LS and early groups were similar to those in the low-salt control group. The percentage of area of subendocardial fibrosis was >6% in the high-salt control, EF, and CS groups and <3% in the LS, early, and low-salt groups. Serial echocardiography demonstrated LS improvement in the LS group; however, the CS and EF groups showed no differences. Conclusions Heart failure–related lung congestion was prevented when ACE-I was administered soon after LS impairment, accompanied by suppression of cardiac hypertrophy and fibrosis, thereby suggesting that the point of no return of myocardial remodeling due to hypertension was present after LS but before CS impairment. There are currently no therapies that can improve prognosis in cases of heart failure (HF) with preserved ejection fraction (EF). We hypothesized that there is a point of no return after which no response to treatment is noted and that for the prevention of hypertensive HF this point may be determined by left ventricle (LV) strain, in the prevention of hypertensive HF. Here an angiotensin-converting enzyme inhibitor (ACE-I) was initiated based on myocardial strain imaging and its effects were determined in an animal model. Thirty-two male Dahl salt-sensitive rats, age 6 weeks, were divided into six experimental groups and compared with low-salt (n = 8) and high-salt control groups (n = 8). In the early treatment group, ACE-I was administered from the age of 6 weeks (n = 4); in the longitudinal strain (LS) group, at 10-12 weeks when LS impairment was >–21% (n = 4); in the circumferential strain (CS) group, at 16-18 weeks when CS impairment was >–18% (n = 4); and in the EF group, at 20 weeks when EF was <55% (n = 4). Subsequently, all rats were sacrificed at 23 weeks age, the LV and lung weight were measured, and pathologic analyses were performed. At 23 weeks of age, the lung and LV weights increased in the high-salt control, EF, and CS groups, whereas the lung and LV weights in the LS and early groups were similar to those in the low-salt control group. The percentage of area of subendocardial fibrosis was >6% in the high-salt control, EF, and CS groups and <3% in the LS, early, and low-salt groups. Serial echocardiography demonstrated LS improvement in the LS group; however, the CS and EF groups showed no differences. Heart failure–related lung congestion was prevented when ACE-I was administered soon after LS impairment, accompanied by suppression of cardiac hypertrophy and fibrosis, thereby suggesting that the point of no return of myocardial remodeling due to hypertension was present after LS but before CS impairment." @default.
• W2989184576 created "2019-11-22" @default.
• W2989184576 creator A5011276506 @default.
• W2989184576 creator A5060144706 @default.
• W2989184576 creator A5060163246 @default.
• W2989184576 creator A5067280358 @default.
• W2989184576 creator A5079895073 @default.
• W2989184576 creator A5082132253 @default.
• W2989184576 date "2020-02-01" @default.
• W2989184576 modified "2023-09-26" @default.
• W2989184576 title "Left Ventricular Longitudinal Strain as a Marker for Point of No Return in Hypertensive Heart Failure Treatment" @default.
• W2989184576 cites W1966912437 @default.
• W2989184576 cites W1976574306 @default.
• W2989184576 cites W1977152294 @default.
• W2989184576 cites W1993208832 @default.
• W2989184576 cites W2013784844 @default.
• W2989184576 cites W2063481915 @default.
• W2989184576 cites W2085786241 @default.
• W2989184576 cites W2098766590 @default.
• W2989184576 cites W2104475665 @default.
• W2989184576 cites W2106683299 @default.
• W2989184576 cites W2124624517 @default.
• W2989184576 cites W2150610527 @default.
• W2989184576 cites W2165392286 @default.
• W2989184576 cites W2178738676 @default.
• W2989184576 cites W2289163020 @default.
• W2989184576 cites W2560800340 @default.
• W2989184576 cites W2601765095 @default.
• W2989184576 cites W2750836961 @default.
• W2989184576 cites W2750973620 @default.
• W2989184576 cites W2773161318 @default.
• W2989184576 cites W2792438939 @default.
• W2989184576 cites W2899487182 @default.
• W2989184576 cites W2901470247 @default.
• W2989184576 cites W3150595609 @default.
• W2989184576 doi "https://doi.org/10.1016/j.echo.2019.08.022" @default.
• W2989184576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31740371" @default.
• W2989184576 hasPublicationYear "2020" @default.
• W2989184576 type Work @default.
• W2989184576 sameAs 2989184576 @default.
• W2989184576 citedByCount "4" @default.
• W2989184576 countsByYear W29891845762021 @default.
• W2989184576 countsByYear W29891845762022 @default.
• W2989184576 crossrefType "journal-article" @default.
• W2989184576 hasAuthorship W2989184576A5011276506 @default.
• W2989184576 hasAuthorship W2989184576A5060144706 @default.
• W2989184576 hasAuthorship W2989184576A5060163246 @default.
• W2989184576 hasAuthorship W2989184576A5067280358 @default.
• W2989184576 hasAuthorship W2989184576A5079895073 @default.
• W2989184576 hasAuthorship W2989184576A5082132253 @default.
• W2989184576 hasConcept C126322002 @default.
• W2989184576 hasConcept C164705383 @default.
• W2989184576 hasConcept C2777099384 @default.
• W2989184576 hasConcept C2778022156 @default.
• W2989184576 hasConcept C2778198053 @default.
• W2989184576 hasConcept C2778921608 @default.
• W2989184576 hasConcept C71924100 @default.
• W2989184576 hasConcept C78085059 @default.
• W2989184576 hasConceptScore W2989184576C126322002 @default.
• W2989184576 hasConceptScore W2989184576C164705383 @default.
• W2989184576 hasConceptScore W2989184576C2777099384 @default.
• W2989184576 hasConceptScore W2989184576C2778022156 @default.
• W2989184576 hasConceptScore W2989184576C2778198053 @default.
• W2989184576 hasConceptScore W2989184576C2778921608 @default.
• W2989184576 hasConceptScore W2989184576C71924100 @default.
• W2989184576 hasConceptScore W2989184576C78085059 @default.
• W2989184576 hasFunder F4320334764 @default.
• W2989184576 hasIssue "2" @default.
• W2989184576 hasLocation W29891845761 @default.
• W2989184576 hasOpenAccess W2989184576 @default.
• W2989184576 hasPrimaryLocation W29891845761 @default.
• W2989184576 hasRelatedWork W2051712573 @default.
• W2989184576 hasRelatedWork W2061321770 @default.
• W2989184576 hasRelatedWork W2077083067 @default.
• W2989184576 hasRelatedWork W2334396920 @default.
• W2989184576 hasRelatedWork W2362265450 @default.
• W2989184576 hasRelatedWork W2375703560 @default.
• W2989184576 hasRelatedWork W2789205885 @default.
• W2989184576 hasRelatedWork W2965474825 @default.
• W2989184576 hasRelatedWork W3033076790 @default.
• W2989184576 hasRelatedWork W4200030969 @default.
• W2989184576 hasVolume "33" @default.
• W2989184576 isParatext "false" @default.
• W2989184576 isRetracted "false" @default.
• W2989184576 magId "2989184576" @default.
• W2989184576 workType "article" @default.